ArticleBreast cancer (Tokyo, Japan)2026
Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Programmed cell death and metastatic evolution in breast cancer: the role of anoikis, necroptosis, and ferroptosis.Apoptosis : an international journal on programmed cell death · 2026Review
- New indole-linked 1,2,4-triazole derivatives as dual FAK inhibitors and apoptosis inducers targeting survival and migration in triple-negative breast cancer in-vitro.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHigh-grade carcinomas, including breast cancer, are associated with angiogenesis and non-angiogenic vascularization. Non-angiogenic vascularization enhances blood flow, tumor growth, and metastasis. Although inhibition of focal adhesion kinase (FAK) is a promising anticancer strategy, its effect on non-angiogenic vascularization remains unknown. We aimed to determine if defactinib, an oral selective FAK inhibitor, suppresses tumor growth by inhibiting non-angiogenic vascularization via reduced cell migration in malignant breast cancer cell lines.
methodsNon-angiogenic vascularization was evaluated in JIMT-1 and MDA-MB-231 cells. Western blotting, fluorescent immunocytochemistry, cell migration assay, time-lapse microscopy, and tube formation assays were performed to evaluate the effects of defactinib. Cells were transfected with siFAK to evaluate off-target effects. The in vivo effects were assessed in orthotopic mouse tumor models, followed by immunohistochemical staining of excised tumor samples.
resultsDefactinib induced changes in cell morphology, migration, and the formation of vascular-like structures in JIMT-1 and MDA-MB-231 cells. Phosphorylation of FAK/PTK2 and its downstream effectors was reduced in defactinib-treated cells. SiRNA-mediated FAK knockdown produced similar effects. Treatment with defactinib suppressed tumor growth in orthotopic mouse tumor models, resulting in tumor shrinkage and reduced macroscopic blood-rich areas. Immunohistochemical staining also revealed a significant reduction in the number of vessels characterized by human serpin family E member 2-a potential indicator of non-angiogenic vascularization-in the defactinib-treated group, with no significant increase in apoptosis.
conclusionsFAK inhibition was shown to suppress non-angiogenic vascularization. Defactinib has the potential to serve as a novel treatment for malignant breast cancer which is resistant to conventional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.